6:18 PM
 | 
Oct 09, 2012
 |  BC Extra  |  Company News

FDA to discuss Novo's insulin products

FDA confirmed the Nov. 8 meeting date for the Endocrinologic and Metabolic Drugs Advisory Committee to discuss NDAs from Novo Nordisk A/S (CSE:NVO; NYSE:NVO)...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >